Is Simponi used for prostate cancer (PSA)?
Simponi (golimumab) is not a treatment for prostate cancer or for lowering PSA (prostate-specific antigen). It is a tumor necrosis factor (TNF) blocker used for immune-mediated conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis—not prostate cancer.
What does “PSA” usually mean here?
“PSA” commonly refers to prostate-specific antigen, a blood test marker used in prostate cancer screening and monitoring. Simponi is not prescribed to reduce PSA levels or to treat prostate cancer.
Could Simponi affect PSA indirectly?
There’s no evidence from the typical prescribing indications that Simponi is intended to change PSA. PSA can rise or fall due to prostate-related factors (like benign prostate enlargement, inflammation/infection, or cancer progression), but that is separate from Simponi’s approved uses.
What’s the right medication path if PSA is the concern?
Management depends on why PSA is elevated and what the prostate evaluation shows (repeat PSA, prostate exam, MRI, biopsy, and risk stratification). Treatment options are usually prostate-cancer–directed (or focused on benign causes), not TNF blockers like Simponi.
If you meant something else by “PSA”
Some people use “PSA” to mean other medical terms (not prostate-specific antigen). If you tell me what PSA stands for in your case (and the condition you’re asking about), I can answer more precisely.